| |
|
SHS Newsletter – To open this newsletter in your browser, please click here.
|
| |
|
|
|
| |
October 2020
|
 |
|
|
|
| |
| |
|
Dear Sir or Madam,
|
| |
In the current SHS Newsletter, we visit with Dr. Marc Struhalla, CEO of our portfolio company c-LEcta, among other things, about how important the enzyme DENARASE® is to the fight against the coronavirus.
Dr. André Zimmermann tells us what challenges small and medium-sized medtech companies have to face and explains why the significance of equity will continue to grow in an era of digital health, MDR and Brexit.
We also report on our latest investment in SALVIA, a Dutch firm specialising in neurological brain stimulation for the effective treatment of migraine patients. Last but not least, we show you what is likely the world’s best medical gait trainer for use in rehabilitation, manufactured by our portfolio company Tyromotion.
I wish you an enjoyable reading experience.
|
| |
|
| |
|
Hubertus Leonhardt
|
|
|
.jpeg)
|
| |
| |
|
Topics
|
| |
| • |
Radical change in medtech!
|
| |
|
|
|
| • |
Arriving at a coronavirus vaccine with enzymes
|
| |
|
|
| • |
Miracor concludes financing round E with 24 million Euros
|
| |
|
|
| • |
World première! Tyromotion presents the first LEXO® medical gait trainer to GLG Fachklinik Wolletzsee
|
| |
|
|
| • |
SHS invests in Salvia, a Dutch-based specialist in neurostimulation
|
| |
|
|
| • |
Inventors' spirit and entrepreneurship honored
|
| |
|
|
|
| • |
Dr. André Zimmermann becomes a member of the jury for InnoHealth USA 2021
|
| |
|
|
| • |
Patrick Frohnheiser appointed to the Tech Tour jury
|
| |
|
|
|
|
|
| • |
Jobs at Portfolio Companies
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
Radical change in medtech! |
|
|
| |
| |
 |
| |
| SHS Partner Dr. André Zimmermann |
|
|
|
We spoke with SHS partner Dr. André Zimmermann about the challenges the healthcare industry faces in these times.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Arriving at a coronavirus vaccine with enzymes |
|
|
| |
| |
.jpeg "Marc_Struhalla.jpg") |
| |
| Dr. Marc Struhalla, Managing Director of c-LEcta GmbH |
|
|
|
In an interview with start-up founder Dr. Marc Struhalla, read about how our portfolio company c-LEcta helps in the production of vaccines against the coronavirus.
|
|
|
|
|
|
| |
| |
|
|
| |
Miracor concludes financing round E with 24 million Euros |
|
|
| |
| |
Miracor raises 24 million Euros, prepares further patient studies and plans market launch for its PiCSO® system.
|
|
|
|
|
.jpeg "Miracor.jpg") |
| |
| The PiCSO® System statistically significantly reduces the size of infarcts |
|
|
|
|
| |
| |
|
|
| |
World première! Tyromotion presents the first LEXO® medical gait trainer to GLG Fachklinik Wolletzsee |
|
|
| |
| |
.jpeg "Lexo.jpg") |
| |
| The Brandenburg Health Minister Ursula Nonnenmacher (3rd from left) at the handover of the LEXO® gait trainer |
|
|
|
Patients with neurological damage often need to learn to walk again, too. The LEXO® gait trainer by Tyromotion is a milestone for patients.
|
|
|
|
|
|
| |
| |
|
|
| |
SHS invests in Salvia, a Dutch-based specialist in neurostimulation |
|
|
| |
| |
‘Salvia’ is the name of our newest portfolio company, and its development is bringing hope to migraine patients.
|
|
|
|
|
.jpeg "Salvia.jpg") |
| |
| Salvia BioElectronics B.V. in Eindhoven |
|
|
|
|
| |
| |
|
|
| |
Inventors' spirit and entrepreneurship honored |
|
|
| |
| |
.jpeg "Monstadt.jpg") |
| |
| Dr.-Ing. Hermann Monstadt (left) at the presentation of the certificate |
|
|
|
phenox GmbH founder Dr.-Ing. Hermann Monstadt becomes honorary professor of the Ruhr-University Bochum.
|
|
|
|
|
|
| |
| |
|
|
|
|
|
| |
Dr. André Zimmermann becomes a member of the jury for InnoHealth USA 2021 |
|
|
| |
| |
.jpeg "AZ_Innohealth.jpg") |
| |
| SHS Partner Dr. André Zimmermann |
|
|
|
SHS partner Dr. André Zimmermann has been appointed to the jury of InnoHealth USA 2021 of the Federal Ministry of Education and Research.
|
|
|
|
|
|
| |
| |
|
|
| |
Patrick Frohnheiser appointed to the Tech Tour jury |
|
|
| |
| |
As a member of the jury, Patrick Frohnheiser is now supporting the Tech Tour community, which connects medtech entrepreneurs and investors worldwide.
|
|
|
|
|
 |
| |
| SHS Investment Manager Patrick Frohnheiser |
|
|
|
|
| |
| |
|
|
|
|
| |
| |
|
|
By the way: From now on, you will regularly receive relevant and up-to-date news about SHS and medical technology on our LinkedIn-Company-Account. Follow us and network with us. Just click here.
|
|
|
|
| |
| |
|
|
|
|
|
| |
Jobs at Portfolio Companies |
|
|
| |
|
|
| |
| |
|
|
|
|
| |
| |
(Junior) Investment Manager (m/f/d)
Read more »
|
|
| |
Entrepreneur (m/f/d) wanted: Management Buy-in/Buy-out (MBI/MBO)
Read more »
|
|
| |
Private Equity & Venture Capital Internship (m/f/d)
Read more »
|
|
|
| |
| |
|
|
|
|
|
|
|
| |
| |
Medical Device Network, 4 September 2020: „Salvia Bioelectronics migraine therapy may offer alternative to drugs“ |
|
| |
Salvia Bioelectronics, a Dutch neurostimulation company targeting chronic migraines, has raised €26m from new and existing investors in a Series A funding round led by Panakès Partners, INKEF Capital and SHS Gesellschaft für Beteiligungsmanagement. |
|
| |
Read more » |
|
|
| |
| |
Frankfurter Allgemeine Zeitung, 11 August 2020: „Schnäppchen in der Medizintechnik“ (Bargains in medical technology) |
|
| |
The Corona crisis is reviving the takeover market for companies in the healthcare sector. Many targets might be cheaper. Others are more expensive than ever. |
|
| |
Read more » |
|
|
| |
| |
Schwäbische Zeitung, 4 August 2020: „SHS Medizintechnikindex nimmt Branche unter die Lupe" (SHS Medical Technology Index takes a close look at the industry) |
|
| |
How has the industry developed in recent years? The SHS Medical Technology Index is intended to show this. "In the evaluation, we can see that the medical technology industry is quite stable compared to the overall economy and has performed better than many other industries in the past ten years," summarizes Hubertus Leonhardt. |
|
| |
Read more » |
|
|
| |
| |
|
|
| |
|
|
| |
Investment focus
|
|
| |
|
|
| |
| Sector: |
|
life sciences (medical technology, diagnostics, applied technologies, digital health, industrial biotechnology/pharmaceutical industry; no drug development) |
| Geographical Focus: |
|
Germany, Austria, Switzerland, Scandinavia, Benelux |
| Reasons for investment: |
|
growth capital, strengthening equity, MBO/MBI, change of shareholders/succession, M&A financing, spin-off |
| Company situation: |
|
growth/expansion, succession/company sale, internationalization; operating profit may be negative for growth, or for technology-related reasons |
| Transaction value and investment size: |
|
transaction value: up to € 100m; investment amount:
€ 2-30m, with a co-investor from the SHS-network up to € 60m |
| Investment types: |
|
majorities or minorities, equity & financial instruments similar to equity |
|
|
| |
|
|
|
|
|
| |
|
|
| |
The newsletter is published by SHS Gesellschaft für Beteiligungsmanagement mbH
|
|
| |
|
|
| |
Bismarckstrasse 12 | 72072 Tuebingen | Germany | www.shs-capital.eu
Tel +49 7071 9169-0 | Fax +49 7071 9169-190
|
|
| |
|
|
| |
|
Editorial team: SHS Gesellschaft für Beteiligungsmanagement mbH
Design and technical realisation: UNIBRAND GmbH
|
|
To unsubscribe the newsletter, please click here. If you like us to delete your data, please send an email with the subject „data deletion“ to tuebingen@shs-capital.eu.
|
|
|
| |
|
|
|
|
| |
|
.jpeg "LinkedIn-Logo_.png")